Malta - angielski - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Malta - angielski - Malta Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Malta - angielski - Malta Medicines Authority

auxilto healthcare s.r.o. bucharova 2657/12, stodulky 158 00 praha 5 , czech republic - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Malta - angielski - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes

Malta - angielski - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Malta - angielski - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Unia Europejska - angielski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Unia Europejska - angielski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Unia Europejska - angielski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Unia Europejska - angielski - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - diabetes mellitus, type 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).